Biofrontera Submits FDA Application to Expand Ameluz® Use
What happened
Biofrontera submitted a supplemental New Drug Application to the FDA. The application seeks to expand the indication for Ameluz® topical gel, 10%, combined with PDT using the RhodoLED® lamp series. If approved, the new indication would allow treatment of mild-to-moderate actinic keratoses on the extremities, neck, and trunk.
From manilatimes.net
Why it matters
The submission reflects Biofrontera's strategy to broaden the clinical utility of its red-light PDT platform. Expanding the approved use of Ameluz® could increase the market size and commercial viability of the treatment.
From manilatimes.net
Who's involved
- BiofronteraBiopharmaceutical company submitting the application to expand drug indication.
- FDARegulatory agency reviewing the drug application for market approval.
- Roswell Park Comprehensive Cancer CenterHospital associated with the research supporting the drug submission.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Geode Capital ManagementSpeculative
Geode Capital Management might see its investment thesis reinforced if the application receives positive regulatory news.
Keep exploring
The entities involved
-
Biofrontera
Nothing else this week.
- FDA